Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

INTRODUCTION: Patients with chronic kidney disease (CKD) remain at risk for kidney and cardiovascular events resulting from residual albuminuria, despite available treatments. Leukotrienes are proinflammatory and vasoconstrictive lipid mediators implicated in the etiology of chronic inflammatory dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Heerspink, Hiddo J.L., Law, Gordon, Psachoulia, Konstantina, Connolly, Kathleen, Whatling, Carl, Ericsson, Hans, Knöchel, Jane, Lindstedt, Eva-Lotte, MacPhee, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589691/
https://www.ncbi.nlm.nih.gov/pubmed/34805632
http://dx.doi.org/10.1016/j.ekir.2021.08.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589691/
https://www.ncbi.nlm.nih.gov/pubmed/34805632
http://dx.doi.org/10.1016/j.ekir.2021.08.018

Ejemplares similares